Download PDF
Semin Liver Dis 2000; 20(2): 185-198
DOI: 10.1055/s-2000-9941
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Antiviral Therapy for Patients with Chronic Hepatitis C

Jenny Heathcote
  • University of Toronto, University Health Network: Toronto Western Hospital, Toronto, Ontario, Canada
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

Several large, randomized, controlled treatment trials in persons with hepatitis C and ongoing hepatitis have been reported recently. These have shown that, in patients without other comorbid conditions, treatment for from 6 to 12 months with a combination of interferon-α2b, 3 MU three times a week (ttw), plus ribavirin, 1,000-1,200 mg daily, results in a higher incidence of sustained virologic response than does treatment with interferon-α2b monotherapy, 3 MU ttw, given for similar durations. Patients who have relapsed after interferon monotherapy may achieve a sustained virologic response when retreated with interferon plus ribavirin for 6 months or when given a higher dose of interferon for a longer duration than the initial treatment. By contrast, patients who had no virologic response to prior interferon monotherapy have only a small chance of achieving a sustained response when similarly retreated. Although the efficacy of treatment for hepatitis C has improved steadily over the last decade, current interferon-based therapies still achieve a sustained virologic response in fewer than half of patients who initiate therapy, are associated with appreciable side effects, and are expensive. Furthermore, the natural history of chronic hepatitis C suggests that even in the absence of therapy, most patients with chronic hepatitis C infection may experience little morbidity or mortality for decades. Finally, published therapeutic trials stem largely from tertiary referral centers, where an especially high level of commitment is expected from both the patients and the team in charge of therapy. Typically, such trials have also excluded patients with comorbid diseases, thus reducing their ``generalizability.'' This review focuses on two fundamental questions about the currently available treatments for this disease: Who should be treated with them? And when should they be treated? Critical analysis suggests that the answers to these questions are not as clear as they may superficially appear.

KEYWORD

interferon - chronic hepatitis C - monotherapy - combination therapies

REFERENCES

  • 1 Maddrey W. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naïve patients.  Seminars Liver Dis . 1999;  19 67-75
    PubMedGoogle Scholar
  • 2 Renault P, Hoofnaagle J. Side effects of alpha interferon.  Semin in Liver Dis . 1989;  9 273-277
    PubMedGoogle Scholar
  • 3 Glue P. The clinical pharmacology of ribavirin.  Sem Liver Dis . 1999;  19 17-24
    PubMedGoogle Scholar
  • 4 Please see www.lhsc.on.ca/casl/ . 
    Google Scholar
  • 5 Consensus statement. EASL international consensus conference on hepatitis C. Paris, 26-28 February 1999.  J Hepatol . 1999;  30 956-961
    CrossrefPubMedGoogle Scholar
  • 6 McHutchison J, Gordon S, Schiff E. Interferon alfa 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.  N Eng J Med . 1198;  339 1485-1492
    PubMedGoogle Scholar
  • 7 Poynard T, Marcellin P, Lee S. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.  Lancet . 1998;  352 1426-1432
    CrossrefPubMedGoogle Scholar
  • 8 Poynard T, McHutchison J, Goodman Z, Ling M, Albrecht J. Is an ``a la carte'' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?.  Hepatology . 2000;  31 211-218
    CrossrefPubMedGoogle Scholar
  • 9 Marcellin P, Boyer N, Gervais A. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy.  Ann Intern Med . 1997;  127 875-881
    PubMedGoogle Scholar
  • 10 Camma C, Di Marco V, Lo Iacono O. Long-term course of interferon-treated chronic hepatitis C.  J Hepatol . 1998;  28 531-537
    CrossrefPubMedGoogle Scholar
  • 11 Lau D, Kleiner D E, Ghany M G, Park Y, Schmid P, Hoofnagle J. 10-Year follow-up after Interferon-α therapy for chronic hepatitis C.  Hepatology . 1998;  28 1121-1127
    CrossrefPubMedGoogle Scholar
  • 12 Niederau C, Lange S, Heintges T. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study.  Hepatology . 1998;  28 1687-1695
    CrossrefPubMedGoogle Scholar
  • 13 Sim H, Yim C, Krajden M, Heathcote J. Durability of serological remission in chronic hepatitis C treated with Interferon alpha-2b.  Am J Gastroenteral . 1998;  93 39-43
    PubMedGoogle Scholar
  • 14 Reichard O, Glaumann H, Fryden A, Norkans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.  J Hepatol . 1999;  30 783-787
    CrossrefPubMedGoogle Scholar
  • 15 Davis G, McHutchison J, Poynard T. Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C [Abstract # 570].  Hepatology . 1999;  30 303A
    PubMedGoogle Scholar
  • 16 Schmidt W S, Wu P, Brashear D. Effect of Interferon therapy on hepatitis C virus RNA in whole blood, plasma and peripheral mononuclear cells.  Hepatology . 1998;  28 1110-1116
    CrossrefPubMedGoogle Scholar
  • 17 Nishiguchi S, Kuroki T, Nakatani S. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.  Lancet . 1995;  346 1051-1055
    CrossrefPubMedGoogle Scholar
  • 18 Mazzella G, Accogli E, Sottili S. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.  J Hepatol . 1996;  24 141-147
    CrossrefPubMedGoogle Scholar
  • 19 Imai Y, Kawata S, Tamura S. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C.  Ann Intern Med . 1998;  129 94-99
    PubMedGoogle Scholar
  • 20 Kasahara A, Hayashi N, Mochizuki K. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C.  Hepatology . 1998;  27 1394-1402
    CrossrefPubMedGoogle Scholar
  • 21 Fattovich G, Giustina G, Degos F. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C.  J Hepatol . 1997;  27 201-205
    CrossrefPubMedGoogle Scholar
  • 22 Yoshida H, Shiratori Y, Moriyama M. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan.  Ann Intern Med . 1999;  131 174-181
    PubMedGoogle Scholar
  • 23 Shiffman M, Hofmann C, Contos M. A randomized controlled trial of maintenance Interferon therapy for patients with chronic hepatitis C virus and persistent viremia.  Gastroenterology . 1999;  117 1164-1172
    CrossrefPubMedGoogle Scholar
  • 24 Seeff L, Buskell-Bales Z, Wright E. Long-term mortality after transfusion-associated non-a, non-b hepatitis.  N Eng J Med . 1992;  327 1906-1911
    CrossrefPubMedGoogle Scholar
  • 25 Vogt M, Lang T, Frosner G. Pevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.  N Eng J Med . 1999;  341 866-870
    CrossrefPubMedGoogle Scholar
  • 26 Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin.  N Eng J Med . 1999;  340 1228-1233
    CrossrefPubMedGoogle Scholar
  • 27 Seeff L B, Miller R N, Rabkin C S. 45 year follow-up of hepatitis C virus infection in healthy young adults.  Ann Intern Med . 2000;  132 105-111
    PubMedGoogle Scholar
  • 28 Ikeda K, Saitoh S, Suzuki Y. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients.  J Hepatol . 1998;  28 930-938
    CrossrefPubMedGoogle Scholar
  • 29 Yano M, Kumada H, Kage M. The long-term pathological evolution of chronic hepatitis C.  Hepatology . 1996;  23 1334-1340
    CrossrefPubMedGoogle Scholar
  • 30 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C.  Lancet . 1997;  349 825-832
    CrossrefPubMedGoogle Scholar
  • 31 Wali M, Lewis S, Hubscher S. Histological progression during short-term follow-up of patients with chronic hepatitis C virus infection.  J Viral Hepat . 1999;  6 445-452
    CrossrefPubMedGoogle Scholar
  • 32 Niederau C, Lange S, Heintges T. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study.  Hepatology . 1998;  28 1687-1695
    CrossrefPubMedGoogle Scholar
  • 33 Garcia-Tsao G, Boyer J. Outpatient liver biopsy: How safe is it?.  Ann Intern Med . 1993;  118 150-153
    PubMedGoogle Scholar
  • 34 Piccinino F, Sagnelli E, Pasquale G. Complications following percutaneous liver biopsy: A multicentre retrospective study on 68,276 biopsies.  J Hepatol . 1986;  2 165-173
    CrossrefPubMedGoogle Scholar
  • 35 Sobelsky R, Mathurin P, Charlotte F. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view.  Gastroenterology . 1999;  116 378-386
    PubMedGoogle Scholar
  • 36 Bonkovsky H, Woolley M, the Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with Interferon therapy.  Hepatology . 1999;  29 264-270
    CrossrefPubMedGoogle Scholar
  • 37 Ware J E, Bayliss M, Mannocchia M, Davis G, the International Hepatitis Interventional Therapy Group. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response.  Hepatology . 1999;  30 550-555
    CrossrefPubMedGoogle Scholar
  • 38 Goh J, Coughlan B, Quinn J, O'Keane J C, Crowe J. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection.  Eur J Gastroenterol Hepatol . 1999;  11 833-838
    PubMedGoogle Scholar
  • 39 Mathurin P, Moussalli J, Cadranel J. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity.  Hepatology . 1998;  27 868-872
    CrossrefPubMedGoogle Scholar
  • 40 Boyer N, Marcellin P, Degott C. Recombinant Interferon-α for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus.  J Infect Dis . 1992;  165 723-726
    PubMedGoogle Scholar
  • 41 Marriott E, Navas S, del Romero J, Garcia S, Castillo I, Quiroga J A, Carreno V. Treatment with recombinant α-interferon of chronic hepatitis C in anti-HIV positive patients.  J Med Virol . 1993;  40 107-111
    PubMedGoogle Scholar
  • 42 Soriano V, Garcia-Samaniego J, Bravo R. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus.  Clin Infect Dis . 1996;  23 585-591
    PubMedGoogle Scholar
  • 43 Collier J, Heathcote J. Hepatitis C viral infection in the immunosuppressed patient.  Hepatology . 1998;  27 2-6
    CrossrefPubMedGoogle Scholar
  • 44 Vogt M W, Hartshorn K L, Furman P A. Ribavirin antagonizes the effect of azidothymidine on HIV replication.  Science . 1987;  27 1376-1379
    PubMedGoogle Scholar
  • 45 Darby S, Ewart D, Giangrande P. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C.  Lancet . 1997;  350 1425-1431
    CrossrefPubMedGoogle Scholar
  • 46 Telfer P, Garson J, Whitby K. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients.  Br J Haematol . 1997;  98 850-855
    CrossrefPubMedGoogle Scholar
  • 47 Lethagen S, Widell A, Berntorp E, Verbaan H, Lindgren S. Interferon and ribavirin treatment in patients with hemophilia or von Willebrand disease infected with hepatitis C: An update [Abstract # 430].  Haemophilia . 1998;  4 263
    PubMedGoogle Scholar
  • 48 Fernandez J L, Rendo P, del Pino N. A double-blind controlled trial of recombinant interferon-α2b in hemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels.  J Viral Hepat . 1997;  4 113-119
    PubMedGoogle Scholar
  • 49 Mathurin P, Mouquet C, Poynard T. Impact of hepatitis B and C on kidney transplantation outcome.  Hepatology . 1999;  29 257-263
    CrossrefPubMedGoogle Scholar
  • 50 Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durant D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients.  Transplantation . 1995;  59 1426-1431
    CrossrefPubMedGoogle Scholar
  • 51 Misiani R, Bellavita P, Fenilli D. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus.  N Eng J Med . 1994;  330 751-756
    PubMedGoogle Scholar
  • 52 Disdier P, Harle J R, Weiller P J. Interferon for mixed cryoglobulinemia associated with hepatitis C.  Am J Med . 1992;  93 115-116
    CrossrefPubMedGoogle Scholar
  • 53 Taillan B, Ferrari E, Garnier G. Low-dose Interferon-α for mixed cryoglobulinemia associated with hepatitis c virus.  Am J Med . 1992;  93 476
    PubMedGoogle Scholar
  • 54 Mazzaro C, Franzin F, Tulissi P. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to α-Interferon therapy.  Cancer . 1996;  77 2604-2613
    CrossrefPubMedGoogle Scholar
  • 55 Ferri C, Zignego G, Longombardo M. Effect of alpha-Interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients.  Infection . 1993;  2 93-97
    PubMedGoogle Scholar
  • 56 Hermine O, Lefrere J, Bronowicki X. Patients with splenic lymphoma with villous lymphocytes associated with hepatitis C infection may enter in complete clinical response after reduction of viral load. American Society of Hematology 41st Annual Meeting, December 6, 1999
    Google Scholar
  • 57 Polzien F, Schott P, Mihm S, Ramadori G, Hartmann H. Interferon-α treatment of hepatitis C virus-associated mixed cryoglobulinemia.  J Hepatol . 1997;  27 63-71
    CrossrefPubMedGoogle Scholar
  • 58 Sarac E, Bastacky S, Johnson J. Response to high-dose Interferon-α after failure of standard therapy in MPGN associated with hepatitis c virus infection.  Am J Kidney Dis . 1997;  30 113-115
    PubMedGoogle Scholar
  • 59 Cresta P, Musset L, Cacoub P. Response to interferon α treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus.  Gut . 1999;  45 122-128
    PubMedGoogle Scholar
  • 60 Wright T, Combs C, Kim M. Interferon-α therapy for hepatitis C virus infection after liver transplantation.  Hepatology . 1994;  20 773-779
    PubMedGoogle Scholar
  • 61 Sheiner P, Boros P, Klion M. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation.  Hepatology . 1998;  28 831-838
    CrossrefPubMedGoogle Scholar
  • 62 Bizollon T, Palazzo U, Ducerf C. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.  Hepatology . 1997;  26 500-504
    CrossrefPubMedGoogle Scholar
  • 63 Charlton M, Seaberg E, Wiesner R, Everhart J. Predictors of patient and graft survival following liver transplantation for hepatitis C.  Hepatology . 1998;  28 823-830
    CrossrefPubMedGoogle Scholar
  • 64 Reddy K, Hoofnagle J, Tong M. Racial differences in responses to therapy with interferon in chronic hepatitis C.  Hepatology . 1999;  30 787-793
    CrossrefPubMedGoogle Scholar
  • 65 McHutchison J, Poynard T, Gordon S. The impact of race on response to anti-viral therapy in patients with chronic hepatitis C [Abstract # 568].  Hepatology . 1999;  30 302A
    PubMedGoogle Scholar
  • 66 Everson G, Jensen D M, Craig J R. Efficacy of Interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics or nonfibrotics.  Hepatology . 1999;  30 271-276
    CrossrefPubMedGoogle Scholar
  • 67 Valla D C, Chevallier M, Marcellin P. Treatment of hepatitis C virus-related cirrhosis: A randomized controlled trial of Interferon alfa-2b versus no treatment.  Hepatology . 1999;  29 1870-1875
    CrossrefPubMedGoogle Scholar
  • 68 Shiratori Y, Yokosuka O, Nakata R. Prospective study of Interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA.  Hepatology . 1999;  29 1573-1580
    CrossrefPubMedGoogle Scholar
  • 69 Heathcote E, Shiffman M, Cooksley G. Multinational evaluation of the efficacy and safety of once-weekly peginterferon alfa 2a (PEG-IFN) in patients with chronic hepatitis C (CHC) with compensated cirrhosis [Abstract # 621].  Hepatology . 1999;  30 316A
    CrossrefPubMedGoogle Scholar
  • 70 Garcia Buey L, Garcia-Monzon C, Rodriguez S. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C.  Gastroenterology . 1995;  108 1770-1777
    PubMedGoogle Scholar
  • 71 Sim K H, Wojcik J P, Margulies M, Wade J, Heathcote J. Human leukocyte antigen class II alleles may affect response of chronic hepatitis C to interferon therapy.  J Viral Hepat . 1998;  5 249-253
    CrossrefPubMedGoogle Scholar
  • 72 Bell H, Hellum K, Harthug S. Genotype, viral load and age as independent predictors of treatment outcome of interferon-α2a treatment in patients with chronic hepatitis C.  Scand J Infect Dis . 1997;  29 17-22
    PubMedGoogle Scholar
  • 73 Tong M, Reddy R, Lee W. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial.  Hepatology . 1997;  26 747-754
    PubMedGoogle Scholar
  • 74 Farrell G, Bacon B, Goldin R, The Clinical Advisory Group for the Hepatitis C Comparative Study. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial.  Hepatology . 1998;  27 1121-1127
    CrossrefPubMedGoogle Scholar
  • 75 Reichard O, Norkrans G, Fryden A. Randomised, double-blind, placebo-controlled trial of interferon alfa 2b with and without ribavirin for chronic hepatitis C.  Lancet . 1998;  351 83-87
    CrossrefPubMedGoogle Scholar
  • 76 Sulkowski M, Reindollar R, Clin C, Yu J. Combination therapy with peginterferon alfa-2a (PEG-IFN) and ribavirin in the treatment of patients with chronic hepatitis C (CHC): A phase II open-label study [Abstract # 145].  Hepatology . 1999;  30 197A
    PubMedGoogle Scholar
  • 77 Gavier B, Martinez-Gonzalez M, Riezu-Boj J. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C.  Gastroenterology . 1997;  113 1647-1653
    PubMedGoogle Scholar
  • 78 Neumann A, Lam N, Dahari H. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alfa therapy.  Science . 1998;  282 103-107
    CrossrefPubMedGoogle Scholar
  • 79 Zeuzem S, Lee J, Franke A. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa.  Hepatology . 1998;  27 1149-1156
    CrossrefPubMedGoogle Scholar
  • 80 McHutchison J G, Gordon S C, Morgan T. Predicting response to initial therapy with interferon alpha and ribavirin in chronic hepatitis C using serum HCV RNA during therapy [Abstract # 818].  Hepatology . 1999;  30 365A
    PubMedGoogle Scholar
  • 81 Brouwer J, Hansen B, Niesters H, Schalm S. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.  J Hepatol . 1999;  30 192-198
    CrossrefPubMedGoogle Scholar
  • 82 Neumann A, Dahari H, Univ B. Early prediction and mechanism of the ribavirin/IFN alpha dual therapy effect on chronic hepatitis C virus (HCV) infection [Abstract # 595].  Hepatology . 1999;  30 309A
    PubMedGoogle Scholar
  • 83 Davis G L, Esteban-Mur R, Rustigi V. Interferon alfa 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C.  N Eng J Med . 1998;  339 1493-1499
    CrossrefPubMedGoogle Scholar
  • 84 Heathcote J, Keefe E, Lee S. Re-treatment of chronic hepatitis C with consensus Interferon.  Hepatology . 1998;  27 1136-1143
    CrossrefPubMedGoogle Scholar
  • 85 Bell H, Hellum K, Harthug S. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with inteferon-alpha2a.  Scand J Gastroenterol . 1999;  34 194-198
    CrossrefPubMedGoogle Scholar
  • 86 Schalm S, Weiland O, Hansen B. et al.  Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials. Gastroenterology . 1999;  117 408-413
    PubMedGoogle Scholar
  • 87 Barbaro G, Di Lorenzo G, Belloni G. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial.  Am J Med . 1999;  107 112-118
    CrossrefPubMedGoogle Scholar
  • 88 Hassoba H M, Bzowej N, Berengner M. Evolution of viral quasispecies in interferon treated patients with chronic hepatitis C infection.  J Hepatol . 1999;  31 618-627
    CrossrefPubMedGoogle Scholar
  • 89 Lindsay K, Davis G, Schiff E. Response to higher doses of Interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial.  Hepatology . 1996;  24 1034-1040
    PubMedGoogle Scholar
  • 90 Roffi L, Colloredo M, Antonelli G. Breakthrough during recombinant Interferon alfa therapy in patients with chronic hepatitis C virus infection: Prevalence, etiology and management.  Hepatology . 1995;  3 645-649
    PubMedGoogle Scholar
  • 91 Heathcote E, James S, Mullen K, Hauser S C, Rosenblate H, Albert D, the Consensus Interferon Study Group. Chronic hepatitis C virus patients with breakthroughs during Interferon treatment can successfully be retreated with Consensus Interferon.  Hepatology . 1999;  30 562-566
    CrossrefPubMedGoogle Scholar
  • 92 Shiffman M, Hofmann C, Thompson E. Relationship between biochemical, virological, and histological response during Interferon treatment of chronic hepatitis C.  Hepatology . 1997;  26 780-785
    PubMedGoogle Scholar
  • 93 Shiffman M L. Use of high-dose interferon in the treatment of chronic hepatitis C.  Semin Liver Dis . 1999;  19(sl) 25-34
    PubMedGoogle Scholar
  • 94 Zarski J P, Maynard-Muet M, Chousterman S. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha Interferon.  Hepatology . 1998;  27 862-867
    CrossrefPubMedGoogle Scholar
  • 95 Boucher E, Jouanolle H, Andre P. Interferon and Ursodeoxycholic Acid combined therapy in the treatment of chronic viral C hepatitis: Results from controlled randomized trial in 80 patients.  Hepatology . 1995;  21 322-327
    CrossrefPubMedGoogle Scholar
  • 96 Sherman K, Sherman S N. Interferon plus thymosin α-1 treatment of chronic hepatitis C infection: A meta analysis.  Therap Viral Hepat . 1998;  48 379-383
    PubMedGoogle Scholar
      >